Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2014

Open Access 01-12-2014 | Research article

Molecular breast cancer subtypes and therapies in a public hospital of Northeastern Brazil

Authors: Ana Cláudia de Macêdo Andrade, Carlos Alberis Ferreira Júnior, Beatriz Dantas Guimarães, Ana Waleska Pessoa Barros, Gibran Sarmento de Almeida, Mathias Weller

Published in: BMC Women's Health | Issue 1/2014

Login to get access

Abstract

Background

The frequencies of molecular breast cancer subtypes vary among different human populations. The Northeastern region of Brazil has a mixed population of African, Indigenous and European ancestry. This retrospective study investigated breast cancer subtypes and applied therapies in a public hospital of Northeastern Brazil.

Methods

Data of 633 patients with invasive breast cancer from 2005 to 2011 were obtained from medical records. Status of hormone receptor (HR), HER2 and Ki67 expression index of 269 out of 633 patients were used to define subtypes of Luminal A and B, HER2 and triple negative (TN) breast cancer. Expression index of Ki67 ≥ 14% was applied to distinguish Luminal A from Luminal B subtypes.

Results

Overall, 185 (68.77%) and 132 (49.07%) patients showed positive hormone receptor (HR+) and positive HER2 (HER2+) tumors. The mean age ranged from 53.33 to 58.25 years for patients with tumors of Luminal B and Luminal A subtypes, respectively (p = 0.0182). In general, 67.39% of patients with TN tumors aged over 50 and 19.57% aged between 31 and 40 years (p = 0.0046). The rate of small tumors (T1: ≤ 2.0 cm) varied from 22.73% to 52.46% for TN and Luminal A subtypes (p = 0.0088). The rate of high graded (G3) tumors was increased for HER2 and TN subtypes (35.29% and 34.28%) compared to Luminal A and Luminal B subtypes (3.92% and 12.62%), respectively (p < 0.0001). The five-year survival rate ranged from 92.86% to 75.00%, for Luminal A, HER2 and TN subtypes, respectively (HR: 0.260 to 1.015; 95% CI: 0.043 to 3.594; p = 0.2589). Patients with HER2 positive (HER2+) breast tumors did not receive immunotherapy and chemotherapy application varied from 54.84% to 86.49% for Luminal A and HER2 subtypes, respectively (p = 0.0131).

Conclusions

The results of this study revealed a high percentage of HER2+ breast tumors and an increased rate of patients with TN tumors aged over 50 years. This emphasizes the need for establishing immunotherapy as an additional therapeutic option to improve clinical outcomes for patients with HER2+ tumors and to investigate the risk factors of TN breast cancer.
Appendix
Available only for authorised users
Literature
1.
Rakha EA: Pitfalls in outcome prediction of breast cancer. J Clin Pathol. 2013, 66: 458-464. 10.1136/jclinpath-2012-201083.CrossRefPubMed
2.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature. 2012, 490: 61-70. 10.1038/nature11412.CrossRef
3.
Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
4.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10: R65-10.1186/bcr2124.CrossRefPubMedPubMedCentral
5.
Perou CM, Sørlie T, Eisen MB, Van de Rijn M, Jeffreyk SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge Ø, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumors. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
6.
Cadoo KA, Fornier MN, Morris PG: Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013, 57: 312-321.PubMed
7.
Blows FM, Driver KE, Schmidt MK, Broeks A, Van Leeuwen FE, Wesseling J, Cheang MC: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. Plos Med. 2010, 7: e1000279-10.1371/journal.pmed.1000279.CrossRefPubMedPubMedCentral
8.
Rakha EA, Reis-Filho JS, Ellis IO: Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010, 120: 293-308. 10.1007/s10549-010-0746-x.CrossRefPubMed
9.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009, 7 (1–2): 4-13.CrossRefPubMedPubMedCentral
10.
Rosner B, Glynn RJ, Tamimi RM, Chen WY, Colditz GA, Willett WC, Hankinson SE: Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013, 178 (2): 296-308. 10.1093/aje/kws457.CrossRefPubMedPubMedCentral
11.
Redondo CM, Gago- Domínguez M, Ponte SM, Enguix Castelo M, Jiang X, Alonso García A, Peña Fernández M, Ausencia Tomé M, Fraga M, Gude F, Martínez ME, Muñoz Garzón V, Carracedo A, Castelao JE: Breast feeding, parity and breast cancer subtypes in a Spanish cohort. PLoS One. 2012, 7: e40543-10.1371/journal.pone.0040543.CrossRefPubMedPubMedCentral
12.
DeSantis C, Ma J, Bryan L, Jemal A: Breast cancer statistics 2013. CA Cancer J Clin. 2014, 64 (1): 52-62. 10.3322/caac.21203.CrossRefPubMed
13.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Shelton Earp H, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
14.
Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, Tang L, Hu Q, Freudenheim JL, Shields PG, Morrison CD, Demissie K, Higgins MJ: Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget. 2014, 5: 237-248.PubMed
15.
Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV: Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS One. 2013, 8: e78259-10.1371/journal.pone.0078259.CrossRefPubMedPubMedCentral
16.
Chen M, Xu R, Turner JW, Warhol M, August P, Lee P: Race and the molecular origins of breast cancer in Chinese women: breast cancer in Chinese women. Ann Surg Oncol. 2012, 19: 4085-4093. 10.1245/s10434-012-2452-x.CrossRefPubMed
17.
Clarke CA, Keegan THM, Yang J, Press DJ, Kurian AW, Patel AH, Lacey Jr JV: Age-specific incidence of breast cancer subtypes: understanding the black–white crossover. JNCI. 2012, 104: 1094-1101. 10.1093/jnci/djs264.CrossRefPubMedPubMedCentral
18.
O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC: Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina breast cancer study. Clin Cancer Res. 2010, 24: 6100-6110.CrossRef
19.
20.
Freitas-Junior R, Reis Gonzaga CM, Aires Freitas NM, Martins E, de Cássia de Maio Dardes R: Disparities in female breast cancer mortality rates in Brazil between 1980 and 2009. Clinics. 2012, 67: 731-737. 10.6061/clinics/2012(07)05.CrossRefPubMedPubMedCentral
21.
22.
Salzano FM, Bortolini MC: The Evolution and Genetics of Latin American Populations. 2002, New York: Cambridge University Press
23.
Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE: Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012, 13: e95-e102. 10.1016/S1470-2045(11)70323-0.CrossRefPubMed
24.
Brito Corrêa P, Pereira Toralles MB, Abe-Sandes K, Bonfim Machado TM, Ferreira Bonfim T, Meyer L, Abe-Sandes C, Nascimento R: Câncer de mama triplo negativo e sua associação com ancestralidade africana. Rev Ci Med Biol. 2010, 9 (Supl.1): 3-7.
25.
Viegas de Carvalho L, Pereira EM, Frappart L, Boniol M, Marques Bernardo W, Tarricone V, Tavtigian S, Southey MC: Molecular characterization of breast cancer in young women. Rev Assoc Med Bras. 2010, 56 (3): 278-287.
26.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
27.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer I. 2009, 101: 736-750. 10.1093/jnci/djp082.CrossRef
28.
Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X, Wang S, Zhang L, Yuan Z: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci. 2012, 103: 1679-1687. 10.1111/j.1349-7006.2012.02339.x.CrossRefPubMedPubMedCentral
29.
El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol. 2012, 7: 170-10.1186/1746-1596-7-170.CrossRefPubMedPubMedCentral
30.
Amadori D, Serra P, Bravaccini S, Farolfi A, Puccetti M, Carretta E, Medri L, Nanni O, Tumedei MM, Kahima J, Masalu N: Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations. Breast Cancer Res Treat. in press
31.
Preat F, Simon P, Noel Preat JC: Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women. Diagn Pathol. 2014, 9: 26-10.1186/1746-1596-9-26.CrossRefPubMedPubMedCentral
32.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, EysteinLønning P and Børresen-Daleb: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
33.
Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007, 16 (Suppl 2): 72-77.CrossRef
34.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer Am Cancer Soc. 2007, 109: 1721-1728.
35.
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006, 24: 5652-5657. 10.1200/JCO.2006.06.5664.CrossRefPubMed
36.
Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006, 37: 1217-1226. 10.1016/j.humpath.2006.04.015.CrossRefPubMed
37.
Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO: Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011, 11: 292-10.1186/1471-2407-11-292.CrossRefPubMedPubMedCentral
38.
Ly M, Antoine M, Dembélé AK, Levy P, Rodenas A, Touré BA, Badiaga Y, Dembélé BK, Bagayogo DC, Diallo YL, Koné AA, Callard P, Bernaudin JF, Diallo DA: High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology. 2012, 83 (5): 257-263. 10.1159/000341541.CrossRefPubMed
39.
Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, Oyebadejo TY, Banjo AA, Deji-Agboola AM, Rakha EA, Green AR, Ellis IO: Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat. 2012, 135: 555-569. 10.1007/s10549-012-2173-7.CrossRefPubMed
40.
Salhia B, Tapia C, Ishak EA, Gaber S, Berghuis B, Hussain KH, DuQuette RA, Resau J, Carpten J: Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Women’s Health. 2011, 11: 44.CrossRefPubMedPubMedCentral
41.
Steward L, Conant L, Gao F, Margenthaler JA: Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol. in press
42.
Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, Xin G, Pei L, Gu S, Li X, Zhao X: Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol. 2014, 2: 245-251.PubMed
43.
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winder EP, Weeks JC: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012, 118: 5463-5472. 10.1002/cncr.27581.CrossRefPubMedPubMedCentral
44.
Sugianto J, Sarode V, Peng Y: Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors. Hum Pathol. 2014, 45 (4): 802-809. 10.1016/j.humpath.2013.11.013.CrossRefPubMed
45.
Taucher S, Rudas M, Mader RM, Gnant M, Dusky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R: Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer. 2003, 98: 2547-2553. 10.1002/cncr.11828.CrossRefPubMed
46.
Cusumano PG, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E, Jerusalem G, Klaase J, De Snoo F, Stork-Sloots L, Dekker-Vroling L, Holzik ML: European inter-institutional impact study of MammaPrint. Breast. in press
47.
Drukker CA, Van den Hout HC, Sonke GS, Brain E, Bonnefoi H, Cardoso F, Goldhirsch A, Harbeck N, Honkoop AH, Koornstra RHT, Van Laarhoven HWM, Portielje JEA, Schneeweiss A, Smorenburg CH, Stouthard J, Linn SC, Schmidt MK: Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. Eur J Cancer. 2014, 50: 1045-1054. 10.1016/j.ejca.2014.01.016.CrossRefPubMed
Metadata
Title
Molecular breast cancer subtypes and therapies in a public hospital of Northeastern Brazil
Authors
Ana Cláudia de Macêdo Andrade
Carlos Alberis Ferreira Júnior
Beatriz Dantas Guimarães
Ana Waleska Pessoa Barros
Gibran Sarmento de Almeida
Mathias Weller
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2014
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/1472-6874-14-110

Other articles of this Issue 1/2014

BMC Women's Health 1/2014 Go to the issue

Research article

HIV risks vary according to type of sex work in a cross-sectional survey from Nagaland, India

Research article

Does South Korea have hidden female smokers: discrepancies in smoking rates between self-reports and urinary cotinine level

Research article

The increased trend in mothers’ hospital admissions for psychiatric disorders in the first year after birth between 2001 and 2010 in New South Wales, Australia

Research article

Women’s experiences following severe perineal trauma: a qualitative study

Research article

Magnitude and risk factors of abortion among regular female students in Wolaita Sodo University, Ethiopia

Research article

Patients’ and physicians’ descriptions of occurrence and diagnosis of endometriosis: a qualitative study from Iran